At the news
? NEUTRALIMPACT 2/10 SC 13G/A filed Nov 9, 2026 at 13:45 ET
Goldman Sachs filed an amended Schedule 13G disclosing a beneficial ownership of 203,129 shares (0.9%) of Karyopharm Therapeutics as of September 30, 2026. This is a routine passive stake update; the stake is very small relative to the company's market cap and represents no material change in investment intent.
- Goldman Sachs Group Inc. and Goldman Sachs & Co. LLC filed an amended Schedule 13G
- Beneficial ownership: 203,129 shares (0.9%) of Karyopharm Therapeutics as of September 30, 2026
- Stake value approximately $203,129 based on filing data
- Filing is a routine passive stake update under Rule 13d-1(b)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access